

# P V Chernyshov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089027/publications.pdf>

Version: 2024-02-01

57  
papers

1,461  
citations

279798

23  
h-index

345221

36  
g-index

61  
all docs

61  
docs citations

61  
times ranked

1451  
citing authors

#	ARTICLE	IF	CITATIONS
1	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e241-e242.	2.4	99
2	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1644-1659.	2.4	85
3	Why quality of life measurement is important in dermatology clinical practice. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 424-431.	2.4	69
4	Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1429-1439.	2.4	61
5	The Evolution of Quality of Life Assessment and Use in Dermatology. Dermatology, 2019, 235, 167-174.	2.1	54
6	Stigmatization and self-perception in children with atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology, 2016, Volume 9, 159-166.	1.8	53
7	Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (<sc>EADV</sc>) Task Force on quality of life. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 576-593.	2.4	53
8	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <sc>TOPICOP</sc> score. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1713-1719.	5.7	52
9	Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 194-208.	2.4	51
10	Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1633-1643.	2.4	51
11	Gender differences in health-related and family quality of life in young children with atopic dermatitis. International Journal of Dermatology, 2012, 51, 290-294.	1.0	50
12	Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 816-827.	2.4	43
13	An international multicenter study on quality of life and family quality of life in children with atopic dermatitis. Indian Journal of Dermatology, Venereology and Leprology, 2013, 79, 52.	0.6	41
14	<sc>EADV</sc> Taskforce's recommendations on measurement of health-related quality of life in paediatric dermatology. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2306-2316.	2.4	40
15	Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1410-1419.	2.4	36
16	Quality-of-Life Research in Acne Vulgaris: Current Status and Future Directions. American Journal of Clinical Dermatology, 2019, 20, 527-538.	6.7	35
17	Comparison of the impairment of family quality of life assessed by disease-specific and dermatology-specific instruments in children with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1221-1224.	2.4	33
18	Gender Differences in Self-assessed Health-related Quality of Life in Children with Atopic Dermatitis. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 19-24.	0.1	31

#	ARTICLE	IF	CITATIONS
19	Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1666-1671.	2.4	30
20	A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient Education Network in Dermatology (OPENED) task force. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 787-796.	2.4	30
21	Quimp (quality of life impairment): an addition to the quality of life lexicon. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e181-e182.	2.4	28
22	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e308-e311.	2.4	27
23	Quality of Life in Hidradenitis Suppurativa: An Update. International Journal of Environmental Research and Public Health, 2021, 18, 6131.	2.6	27
24	May the Gender of a Parent Influence Assessment of Health-Related Quality of Life, Family Impact and Severity of Atopic Dermatitis in Children?. Pediatric Dermatology, 2009, 26, 99-100.	0.9	25
25	An International Multi-center Study on Self-assessed and Family Quality of Life in Children with Atopic Dermatitis. Acta Dermatovenereologica Croatica, 2015, 23, 247-53.	0.1	25
26	Epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 612-617.	2.4	24
27	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e362-e365.	2.4	24
28	Comparative study of the quality of life of children with atopic dermatitis from Ukraine and the Czech Republic. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1483-1484.	2.4	23
29	Creation and pilot test results of the dermatology-specific proxy instrument: the Infants and Toddlers Dermatology Quality of Life. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2288-2294.	2.4	22
30	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e839-e842.	2.4	22
31	Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 318-328.	2.4	22
32	Dermatological quality of life instruments in children. Giornale Italiano Di Dermatologia E Venereologia, 2013, 148, 277-85.	0.8	20
33	Health-related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 37-43.	0.8	20
34	Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1614-1621.	2.4	18
35	Validation of the dermatology-specific proxy instrument the Infants and Toddlers Dermatology Quality of Life. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1405-1411.	2.4	17
36	Quality of life measurement in occupational skin diseases. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Occupational Skin Disease. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1924-1931.	2.4	17

#	ARTICLE	IF	CITATIONS
37	Prospective study on hand dermatitis in nurses and doctors during <sc>COVID</sc> â€19 pandemic and its improvement by use of adopted recommendations of the European Academy of Dermatology and Venereology Task Force on Contact Dermatitis. <i>Dermatologic Therapy</i> , 2020, 33, e14396.	1.7	12
38	Randomized, placebo-controlled trial on clinical and immunologic effects of probiotic containing<i>Lactobacillus rhamnosus</i>R0011 and<i>L. helveticus</i>R0052 in infants with atopic dermatitis. <i>Microbial Ecology in Health and Disease</i> , 2009, 21, 228-232.	3.5	11
39	Quality of life assessment in core outcome sets: A position statement of the EADV Task Force on Quality of Life and Patient Oriented Outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 20-23.	2.4	9
40	Expression of activation inducer molecule (CD69) on CD3<sup>+</sup>CD8<sup>+</sup> T lymphocytes in children with atopic dermatitis correlates with SCORAD but not with the age of patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 462-463.	2.4	7
41	Initial validation of the epidermolysis bullosaâ€specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire. <i>Dermatologic Therapy</i> , 2020, 33, e14128.	1.7	7
42	Quality of Life of Infants, Toddlers and Preschoolers with Seborrheic, Allergic Contact and Atopic Dermatitis Before and During COVID-19 Pandemic. <i>Dermatology and Therapy</i> , 2021, 11, 2017-2026.	3.0	7
43	Human papillomavirus: vaccination, related cancer awareness, and risk of transmission among female medical students. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2019, 28, .	0.1	6
44	Hidradenitis suppurativaâ€specific, patientâ€reported outcome measures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1420-1421.	2.4	5
45	Position statement on the role of nurses in therapeutic patient education in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2143-2148.	2.4	5
46	Quality of Life of School and University Students with Acne. <i>Acta Dermatovenerologica Croatica</i> , 2018, 26, 139-145.	0.1	5
47	B7â€2/CD28 costimulatory pathway in children with atopic dermatitis and its connection with immunoglobulinâ€, intracellular interleukinâ€4 and interferonâ€gamma production by Tâ€cells during a 1â€month followâ€up. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 656-659.	2.4	4
48	Differences in human papilloma virus vaccination prevalence, testing, knowledge on vaccination, cancer awareness and sexual activities between male and female medical and nonâ€medical students. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2902-2906.	2.4	4
49	What Health-related Quality of Life Factors Influence the Decision of Patients with Acne to Visit a Dermatologist?. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2018, 11, 21-25.	0.1	4
50	Pilot study on <sc>HPV</sc>â€related cancer awareness and <sc>HPV</sc> vaccination in Ukrainian students. <i>International Journal of Dermatology</i> , 2017, 56, e129-e130.	1.0	3
51	International pilot tests of the epidermolysis bullosaâ€specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e123-e124.	2.4	3
52	Selection process of measures for core outcome set should utilize the highest methodology level and should be maximally free of bias. Comment on â€IDQoL, CDLQI and the 45â€item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: a group discussion studyâ€™. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e208-e209.	2.4	3
53	Testing for HIV prior to methotrexate administration. Is it an obligatory procedure?. <i>International Journal of Dermatology</i> , 2006, 45, 998-999.	1.0	2
54	Comment on: Quimp: A word meaning â€equality of life impairmentâ€. <i>Acta Dermato-Venereologica</i> , 2017, 97, 425.	1.3	1

#	ARTICLE	IF	CITATIONS
55	Soluble TNF-receptors, naive CD31+ T cells and B-1a cells in psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 775-776.	2.4	0
56	Patients's needs and psoriasis treatment. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1404-1405.	2.4	0
57	Risk Factors for HIV Transmission and HIV Testing Among Medical Students. Acta Dermatovenerologica Croatica, 2020, 28, 2-8.	0.1	0